LTE Praising ECT in World Journal of Clinical Cases

Out on PubMed, from authors in China, is this LTE:

Electroconvulsive therapy plays an irreplaceable role in treatment of major depressive disorder.

Ma ML, He LP.World J Clin Cases. 2022 Jun 6;10(16):5515-5517. doi: 10.12998/wjcc.v10.i16.5515.PMID: 35812666 

The abstract is copied below:


Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder.

Keywords: Depression; Electroconvulsive therapy; Major depressive disorder; Somatic cell therapy.

The letter is here.

And the text is here:

This LTE, despite some peculiarities (possibly due to language) is a nice defense of ECT, with musings on mechanisms of action.
WJCC is a low-impact factor, open access journal, but, as we know, any support for ECT is most welcome in the literature, so kudos to these authors.




Comments

Popular posts from this blog

ECT vs Ketamine: NEJM Article Sets Up False Equivalency

RUL ECT vs Low Amplitude Seizure Therapy (LAP-ST)

ECT For Children at a University Hospital: New Study in JECT